• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by GlycoMimetics Inc.

    11/27/24 2:22:44 PM ET
    $GLYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLYC alert in real time by email
    SC 13G 1 glyc13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)

    GlycoMimetics, Inc.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    38000Q102

    (CUSIP Number)

    November 25, 2024

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 38000Q102

     

     

    1.Names of Reporting Persons.

    Logos Global Management LP

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 5,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 5,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.8%

     

    12.Type of Reporting Person (See Instructions) IA, PN

     2 
    CUSIP No. 38000Q102

     

     

    1.Names of Reporting Persons.

    Logos Global Management GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 5,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 5,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.8%

     

    12.Type of Reporting Person (See Instructions) HC, OO

     

     3 
    CUSIP No. 38000Q102

     

     

    1.Names of Reporting Persons.

    Arsani William

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 5,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 5,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.8%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 38000Q102

     

     

    1.Names of Reporting Persons.

    Logos Global Master Fund LP

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ___X__

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Cayman Islands

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 5,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 5,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.8%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     5 
    CUSIP No. 38000Q102

     

     

    1.Names of Reporting Persons.

    Logos GP LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)

    (b) X

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 5,000,000
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 5,000,000

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,000,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.8%

     

    12.Type of Reporting Person (See Instructions) OO

     

     6 
    CUSIP No. 38000Q102

     

     

    Item1.
    (a)Name of Issuer

    GlycoMimetics, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    9708 Medical Center Drive, Rockville, MD 20850

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    Logos Global Master Fund LP (“Global Fund”), Logos Global Management LP (“Logos Global”), Logos GP LLC (“Logos GP”), Logos Global Management GP LLC (“Logos Global GP”), and Arsani William (collectively, the “Filers”).

     

    Logos Global is the investment adviser to investment funds, including Global Fund. Logos Global GP is the general partner of Logos Global. Dr. William is a control person of Logos Global and Logos Global GP.

     

    The Filers are filing this statement jointly but not as members of a group, and they expressly disclaim membership in a group. In addition, filing this Schedule 13G on behalf of Global Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

    (b)The principal business office of the Filers is located at:

    One Letterman Drive, Building C, Suite C3-350, San Francisco, California 94129

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock.

     

    (e)The CUSIP number of the Issuer is: 38000Q102.
     7 
    CUSIP No. 38000Q102

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to Logos Global.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G) as to Logos Global GP and Dr. William.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 64,483,958 shares of Common Stock outstanding as of November 13, 2024, as reported in the Form 10-Q filed by the Issuer on November 13, 2024.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Global Fund holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of Logos Global, Logos Global GP and Dr. William:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Global Fund and Logos GP:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. 38000Q102

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 27, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

     9 
    CUSIP No. 38000Q102

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Logos Global Management LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Act, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: November 27, 2024

     

     

     

    /s/ Arsani William
    Arsani William

     

     
    Logos Global Management LP


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

    Logos Global Master Fund LP

     

    By Logos Global Management LP, its investment manager and attorney-in-fact

     

    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

    Logos Global Management GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Member

     

    Logos GP LLC


    By: /s/ Arsani William
    Name: Arsani William
    Title: Managing Partner

     

     

    Get the next $GLYC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GLYC

    DatePrice TargetRatingAnalyst
    3/21/2025Overweight
    Cantor Fitzgerald
    7/26/2024Buy → Hold
    TD Cowen
    12/22/2023$12.00Overweight
    CapitalOne
    11/12/2021$3.00 → $4.00Hold → Buy
    Jefferies
    More analyst ratings

    $GLYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on GlycoMimetics

      Cantor Fitzgerald initiated coverage of GlycoMimetics with a rating of Overweight

      3/21/25 8:14:54 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics downgraded by TD Cowen

      TD Cowen downgraded GlycoMimetics from Buy to Hold

      7/26/24 7:49:13 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on GlycoMimetics with a new price target

      CapitalOne initiated coverage of GlycoMimetics with a rating of Overweight and set a new price target of $12.00

      12/22/23 7:25:28 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

      —GlycoMimetics Board of Directors approves 1-for-100 reverse stock split— GlycoMimetics, Inc. (NASDAQ:GLYC) ("GlycoMimetics") today announced that its stockholders have approved the proposed merger (the "Merger") with Crescent Biopharma, Inc. ("Crescent"), along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics' special meeting in lieu of the annual meeting of stockholders held on June 5, 2025 (the "Special Meeting"), including a reverse stock split of GlycoMimetics' common stock to be effected at the discretion of the board of directors of GlycoMimetics (the "Board") within the parameters approved by GlycoMimetics' stockholders. On June 5, 2025, f

      6/5/25 4:01:00 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

      WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced that management is scheduled to present at the Jefferies Global Healthcare Conference in New York on Thursday, June 5, 2025, at 11:05 a.m. ET. A live webcast of the presentation will be available at https://wsw.com/webcast/jeff319/cresc/1993344, and an archived replay will be accessible for 90 days following the event. In October 2024, Crescent entered into an acquisition agreement with GlycoMimetics, Inc. (NASDAQ:GLYC). Following c

      5/29/25 7:30:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Crescent Biopharma Appoints David Lubner to Board of Directors

      Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

      4/28/25 7:30:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    SEC Filings

    See more
    • GlycoMimetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure

      8-K - GLYCOMIMETICS INC (0001253689) (Filer)

      6/18/25 5:28:58 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - GLYCOMIMETICS INC (0001253689) (Filer)

      6/6/25 8:30:34 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 425 filed by GlycoMimetics Inc.

      425 - GLYCOMIMETICS INC (0001253689) (Subject)

      5/30/25 8:30:55 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Rock Edwin bought $78,824 worth of shares (305,000 units at $0.26), increasing direct ownership by 81% to 680,403 units (SEC Form 4)

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      6/24/24 4:29:48 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), increasing direct ownership by 33% to 70,643 units (SEC Form 4)

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      6/20/24 4:15:39 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Rock Edwin bought $90,256 worth of shares (65,403 units at $1.38), increasing direct ownership by 21% to 375,403 units

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      9/25/23 4:21:40 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Leadership Updates

    Live Leadership Updates

    See more
    • Crescent Biopharma Appoints David Lubner to Board of Directors

      Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced the appointment of David Lubner to its board of directors.   "David brings extensive experience in senior executive and board roles with particular expertise in finance, operations and corporate strategy," said Peter Harwin, chairman of Crescent's Board of Directors. "His contributions to Crescent will be instrumental as we continue to grow, advance

      4/28/25 7:30:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

      GlycoMimetics, Inc. (NASDAQ:GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as w

      9/6/22 7:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations

      GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Dr. Deepak Tiwari has joined the Company as Vice President, Technical Operations. "Dr. Tiwari brings over 25 years of diverse CMC experience. He has contributed to more than 30 regulatory submissions and 15 commercial product launches throughout his career. As we continue to move uproleselan forward, Deepak's breadth of experience and leadership is a valuable addition to GlycoMimetics," commented Harout Semerjian, GlycoMimetics' Chief Executive Officer. Dr. Tiwari joins the Company from Rafael Pharmaceuticals where he was Vice President and Head of CMC Operations working on development of devimistat in multiple indications including p

      3/2/22 9:15:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • What Does the Recent Purchase at GlycoMimetics Inc. on Jun 20 Indicate?

      Recently, on June 20, 2024, an insider purchase was made at GlycoMimetics Inc., grabbing the attention of investors. According to the SEC Form 4 filing, SVP Finance, CFO Hahn Brian M. bought $4,335 worth of shares (17,500 units at $0.25), boosting direct ownership by 33% to 70,643 units. Insider transactions are closely monitored by investors as they can provide insights into the company's prospects and the confidence of insiders in the business. Let's delve deeper into the recent insider purchase and analyze any potential patterns or significance in comparison to other insider transactions at GlycoMimetics Inc. In early April 2024, Goldberg Mark Alan was granted 4,584 shares, augmenting di

      6/20/24 6:20:00 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Financials

    Live finance-specific insights

    See more
    • GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

      Following closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26 Crescent pipeline also includes two novel antibody-drug conjugates with topoisomerase inhibitor payloads, CR-002 and CR-003 Concurrent financing of approximately $200 million anticipated to fund operations through 2027 Companies to hold a conference call on Tuesday October 29, at 8:00am EDT GlycoMim

      10/29/24 7:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

      Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3

      6/4/24 7:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

      Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy used in the study Comprehensive data analysis with medical, statistical, and regulatory experts underway and will be shared as appropriate; company will submit results for presentation at an upcoming medical meeting National Cancer Institute (NCI) Phase 2/3 study in newly diagnosed AML patients remains ongoing Conference call and webcast to be hosted today, May 6, 2024, at 8:30 a.m. ET. GlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company

      5/6/24 6:00:00 AM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Im Ellie Eunkyung

      3 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

      6/30/25 4:21:21 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Bispham Barbara Harlin

      3 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

      6/30/25 4:16:25 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Moran Susan

      4 - GLYCOMIMETICS INC (0001253689) (Issuer)

      6/23/25 6:51:54 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by GlycoMimetics Inc.

      SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

      11/27/24 2:22:44 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GlycoMimetics Inc.

      SC 13G/A - GLYCOMIMETICS INC (0001253689) (Subject)

      11/12/24 4:30:27 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GlycoMimetics Inc.

      SC 13G - GLYCOMIMETICS INC (0001253689) (Subject)

      11/6/24 5:41:38 PM ET
      $GLYC
      Biotechnology: Pharmaceutical Preparations
      Health Care